Abstract
The secretion of interleukin-10 by both malignant and immune cells promotes the progression of lung tumors, hence negatively impacting on patient prognosis. As interleukin-10 mediates oncogenic effects through the PI3K/AKT signaling pathway, PI3K/AKT inhibitors might sensitize cancer cells to chemotherapy, thus favoring tumor regression and improving disease outcome.
Original language | English |
---|---|
Article number | e25854 |
Journal | OncoImmunology |
Volume | 2 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2013 |
Keywords
- CIP2A
- HPV
- IL-10
- IL-10R
- Lung cancer
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology